1 µg/ml were considered as susceptible (4,10). Whole sequences of the gyrA, gyrB, parC, 2 and parE of the NAL-resistant strains were determined by PCR and direct sequencing. 3
To prepare template DNA, one loopful colony of each strain was resuspended in 100 µl 4 of 20mM Tris-2mM EDTA buffer (pH 7.5) and incubated at 100 PCR purification column (QIAGEN, Valencia, CA), the PCR product was sequenced by 12 using a Big Dye terminator (version 3.1, Applied Biosystems, Foster City, CA).The 13 primers used for PCR and direct sequencing are listed in Table 1 . 14 The results showed in Table 2 . These six strain were erythromycin-sensitive, but 15
showed high-level resistance (>256 µg/ml) to NAL and decreased susceptibilities to 16 fluoroquinolones. All the NAL-resistant strains showed the same mutation in the 17 quinolone resistance-determining regions (QRDRs: e.g. in Escherichia coli at positions 18 Pulsed-field gel electrophoresis (PFGE) analysis (16) for XbaI-digested DNAs showed 1 different patterns among the NAL-resistant strains tested (Fig. 1) . 2
To our knowledge, this is the first report of quinolone resistance in B. pertussis. 3
All the strains were isolated from children and were genetically and epidemiologically 4 unrelated. Although fluoroquinolones are not usually prescribed for children, they are 5 widely used to treat respiratory tract infections in adults (2). In the vaccination era, an 6 increasing proportion of pertussis cases occur in adults and adolescents with lost These quinolone-resistance patterns are quite different those of our NAL-resistant 13 strains. Therefore, the single QRDR mutation in gyrA may constitute the main 14 mechanism of quinolone resistance among the strains tested here. 
